Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CLONAZEPAM Cause Disturbance in attention? 437 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 437 reports of Disturbance in attention have been filed in association with CLONAZEPAM (Clonazepam). This represents 1.1% of all adverse event reports for CLONAZEPAM.

437
Reports of Disturbance in attention with CLONAZEPAM
1.1%
of all CLONAZEPAM reports
11
Deaths
156
Hospitalizations

How Dangerous Is Disturbance in attention From CLONAZEPAM?

Of the 437 reports, 11 (2.5%) resulted in death, 156 (35.7%) required hospitalization, and 71 (16.2%) were considered life-threatening.

Is Disturbance in attention Listed in the Official Label?

Yes, Disturbance in attention is listed as a known adverse reaction in the official FDA drug label for CLONAZEPAM.

What Other Side Effects Does CLONAZEPAM Cause?

Drug ineffective (5,088) Toxicity to various agents (4,028) Completed suicide (3,320) Drug abuse (3,287) Off label use (2,590) Anxiety (2,376) Somnolence (2,260) Dyspnoea (1,987) Depression (1,838) Insomnia (1,836)

What Other Drugs Cause Disturbance in attention?

LEVOTHYROXINE (1,718) METHYLPHENIDATE (1,414) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (1,321) DULOXETINE (986) PREGABALIN (950) LISDEXAMFETAMINE DIMESYLATE (911) OXYCODONE (829) QUETIAPINE (747) ACETAMINOPHEN\HYDROCODONE (746) ACETAMINOPHEN\OXYCODONE (734)

Which CLONAZEPAM Alternatives Have Lower Disturbance in attention Risk?

CLONAZEPAM vs CLONIDINE CLONAZEPAM vs CLOPIDOGREL CLONAZEPAM vs CLOPIDOGREL BESILATE CLONAZEPAM vs CLOPIDOGREL BISULFATE CLONAZEPAM vs CLORAZEPATE

Related Pages

CLONAZEPAM Full Profile All Disturbance in attention Reports All Drugs Causing Disturbance in attention CLONAZEPAM Demographics